NRAS and angiosarcoma: Fitting previous studies of angiosarcomas (Behjati et al., 2014; Murali et al., 2015; Painter et al., 2020), in 3 of 19 analyzed angiosarcomas (16%) activating RAS mutations [2 HRAS (Q61) and 1 NRAS (G12)] were identified.